Sector Alpha Week of 2026-09-11
Not SEBI Registered !! Not Investment advice !!
Sector Alpha — machine-written from the numbers · Data as of 2026-09-11

DMCC Speciality Chemicals Ltd

DMCC
Speciality Chemicals

DMCC Speciality Chemicals Ltd is coiled. The quarters are improving, yet the P/E sits at the 24th percentile of its own 9-year range — the business is moving before the market.

The sharpest disagreement: annual EPS moved +27.0% against a −4.9% price move — the market has not yet caught up with the delivery.

The price is in a confirmed uptrend (4 weeks in) while the P/E sits at the 24th percentile of its own 9-year range. Underneath, the last four quarters read improving — profit +150.0% year on year, and 95% of the last 3 years' profit arrived as cash. What settles it: whether the price catches up with earnings that have already moved.

Stage
Mixed
partial read
Price
₹288
−4.9% 1Y
P/E
17.9×
24th pctile
of its own 9-year range
Revenue (Jun 26)
₹253 Cr
+99.2% YoY
Profit (Jun 26)
₹20.0 Cr
+150.0% YoY
Operating margin
13.0%
flat YoY
ROCE
15%
FY26
ROIC
11.1%
vs WACC 12.0% → −0.9 pp
Cash conversion
95%
of profit, last 3 FY
Unverified figures: Some figures on this page come from a second financial-data feed that could not be cross-checked against the primary source — the two do not share enough overlapping reported history to compare. They are drawn, because they are the only evidence there is, and every section carrying one is marked unverified. PEG is the exception: the quarterly curve is not drawn at all. PEG asks what is being paid for growth — both sides of that division come from the source that could not be checked, so it is withheld instead of marked.
01 · Price story

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

DMCC Speciality Chemicals Ltd trades at ₹288, in a confirmed uptrend and 4 weeks into that stage. That is +6.4% against its own 200-day average. It sits at 71% of a 52-week range of ₹207 to ₹321. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 8 straight weeks.

Today the stock is in a confirmed uptrend — week 4 of stage 2, confirmed. At ₹288 it trades +6.4% versus its 200-day average and sits at 71% of its 52-week range (₹207–₹321).

Sep 26: ₹288 Weekly closing price (₹) with 50- and 200-day averages; shaded bands mark the price stage (grey base, green advance, amber top, red decline). 3-year window.
+6.4% versus the 200-day line, week 4 of stage 2
Price50-day avg200-day avg
S2S4S2S4S2S4S3₹405₹352₹299₹245₹192₹288₹271Sep 23Jun 24Mar 25Jan 26Sep 26
S2S4S2S4S2S4S3₹405₹352₹299₹245₹192₹288₹271Sep 23Mar 25Sep 26
Beating or trailing, week by week since 2016 Each cell is one week from 2016 to now (554 weeks): the stock's trailing 13-week return minus the NIFTY 500's, green ahead / red behind (±25% ramp). Grey cells are the 13-week warm-up or weeks where the NIFTY 500 reading is not held.
trailing 13-week return vs the NIFTY 500
Mar 16Sep 26

Against the market, two honest reads. Cumulative: over the last 10.5 years the stock moved +396% while the NIFTY 500 moved +267% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 8 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

02 · Valuation

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

DMCC Speciality Chemicals Ltd trades at 17.9× P/E, near the bottom of its own range — cheaper only 24% of the time. Its long-run median P/E is 28.6×, measured across 8.7 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 17.9× is near the bottom of its own range — cheaper only 24% of the time, against a long-run median of 28.6× measured over 8.7 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

P/E 17.9× vs a 28.6× long-run median P/E, weekly (left axis); earnings per share, trailing twelve months, weekly (right axis). 8.7-year window; loss-period spikes above 86× shown pinned at the top. The eps (ttm) bars are red where the reading is lower than the quarter before.
near the bottom of its own range — cheaper only 24% of the time
P/EMedianEPS (TTM) (quarterly)
92.5×₹19.969.4×₹15.046.2×₹10.023.1×₹5.00.0×₹0.0×18.00×₹16Dec 17Feb 20May 22Aug 24Sep 26
92.5×₹19.969.4×₹15.046.2×₹10.023.1×₹5.00.0×₹0.0×18.00×₹16Dec 17May 22Sep 26
P/E
17.9×
24th percentile of 9y

Why the multiple sits where it does: over the past year annual EPS moved +27.0% against a −4.9% price move — earnings outran the price, pushing the multiple DOWN its own range.

The price move, decomposed: over 5y, of the −2.8%/yr price move, ~+2.8%/yr came from earnings growth and ~−5.6 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.

A quarterly PEG curve, which only the second data source carries, is not drawn on this page: its two data sources do not share enough overlapping reported history to be compared. A figure nobody could check is not used to price growth — the gap is a decision, not missing data.

03 · What the price assumes

What the price assumes This reading works the multiple backwards. It asks one question: what yearly rate of profit growth is a buyer at the market price already paying for? The number is the growth rate that makes eleven years of profit — six years growing, then five fading — add up to that day's market price, once each year is discounted at 11% a year.

Solved at its 13 June 2026 price, DMCC Speciality Chemicals Ltd was paying for profit growth of about 13.5% a year. Profit itself has compounded 5.3% a year over the past 9 years. Today the market pays 17.9× P/E, the 24th percentile of its own 9-year range.

What the two numbers say together. The multiple is low against its own past, and the growth the price is paying for is far above what this company has actually delivered. A multiple that looks low because earnings fell is not the same thing as a low bar to clear.

How to hold this number: it is a reading of one day's price, taken on 13 June 2026, not a running figure — every other number on this page, the multiple included, is read off the live quote as of 11 September 2026. A higher price is paying for more growth and a lower price for less, so it moves whenever the price does, and this page does not restate it between measurements.

04 · Stage: Mixed

Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

DMCC Speciality Chemicals Ltd reads as mixed on its fundamental arc. Mixed — growth is normalizing off a hyper-growth base: profit growth has eased from +115.4% at its peak to +42.9% but is still expanding, ROCE lifting at 15.0%. The read is built from 8 quarters across 4 curves, on partial evidence.

Growth, year by year: revenue +35.0% in FY26, profit +22.7% Year-over-year growth per fiscal year, %: revenue (left axis); net profit and EPS (right axis — profit growth swings far wider). Zero line drawn.
Revenue YoYProfit YoYEPS YoY
69%311%46%210%23%108%0.0%6.2%−24%−96%%%35%22.7%FY17FY21FY26
69%311%46%210%23%108%0.0%6.2%−24%−96%%%35%22.7%FY17FY21FY26
Three growth curves, twelve quarters Year-on-year growth of trailing-twelve-month revenue (left axis), profit and EPS (right axis — they swing far wider), % at each quarter-end. A missing point means that reading is not held for the quarter.
the trajectory the stage is read from · revenue stabilising, profit rolling over
RevenueProfitEPS
53%226%41%172%28%117%16%63%3.0%8.8%%%49.7%42.9%43.3%Sep 23Dec 24Jun 26
53%226%41%172%28%117%16%63%3.0%8.8%%%49.7%42.9%43.3%Sep 23Dec 24Jun 26
ROCE Annual readings — the quarterly balance-sheet pieces this curve needs are not held for this stock, so the returns read moves once a year and carries less weight in the call.
the return curve, annual readings
ROCE
16%13%11%8.7%6.4%%15%FY23FY24FY26
16%13%11%8.7%6.4%%15%FY23FY24FY26
Revenue growth
Steady high
latest +49.7% · span +6.5% to +49.7%
Profit growth
Rolling over
latest +42.9% · span +23.8% to +211.1%
EPS growth
Rolling over
latest +43.3% · span +25.5% to +184.7%
ROCE
Rising
latest 15.0% · span 7.0%–15.0%

Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.

Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.

A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.

Compound annual growth rate (%) Compound annual growth rate over each window, %. Revenue, profit and EPS from fiscal-year figures; share price is the price CAGR over the same spans. A dash = that window is not held, or the base was a loss.
1yr3yr5yr10yr
Revenue+35.0%+14.6%+23.8%
Profit+22.7%+56.8%−3.9%
EPS+27.0%+58.0%−3.4%
Share price−4.9%−5.5%−2.8%+14.8%
Revenue YoY (Jun 26)
+99.2%
latest quarter vs a year ago
Profit YoY (Jun 26)
+150.0%
latest quarter vs a year ago
Revenue 10y
14.3%
long-run compound pace
05 · 4-Factor Sector Score

4-Factor Sector Score

56.8/100 — rank 8 of 28 in Speciality Chemicals · 80% evidence confidence

DMCC Speciality Chemicals Ltd scores 56.8 out of 100 against the 28 companies it is compared with in Speciality Chemicals, ranking 8. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

The four contributions add to the total exactly: 24.4 + 11 + 11.4 + 10 = 56.8. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

06 · Revenue

Revenue Revenue is the top line: everything the company billed its customers in the period.

DMCC Speciality Chemicals Ltd reported ₹253 Cr of revenue in the Jun 26 quarter, +99.2% year on year. That is the 8th straight quarter of year-on-year growth. Over 9 years it has compounded at 14.3% a year. The last full year, FY26, came in at ₹582 Cr. The last four reported quarters add to ₹708 Cr.

FY26 revenue came in at ₹582 Cr (+35.0% on the year), capping 9 years at 14.3% compound. The latest quarter (Jun 26) printed ₹253 Cr, +99.2% year on year — the 8th consecutive quarter of year-over-year growth.

FY26 revenue ₹582 Cr (+35.0% YoY) Revenue bars, ₹ Cr (left); YoY growth-% line (right). 10-year window. A bar is red when it is lower than the year before.
14.3% a year over 9 years
RevenueYoY growth
62969%47146%31423%1570.0%0−24%₹ Cr%₹58235%FY17FY21FY26
62969%47146%31423%1570.0%0−24%₹ Cr%₹58235%FY17FY21FY26
Jun 26: ₹253 Cr (+99.2% YoY) Quarterly revenue bars, ₹ Cr (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
8th straight quarter of growth
Revenue (quarterly)YoY growth
273108%20576%13743%6811%0−22%₹ Cr%₹25399.2%Sep 23Dec 24Jun 26
273108%20576%13743%6811%0−22%₹ Cr%₹25399.2%Sep 23Dec 24Jun 26

Pace check: the last four quarters averaged +48.0% growth against the decade's 14.3% — the current year is running faster than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +49.7% over the last 4 quarters against +47.1%/yr over the last 8 — stabilising; TTM profit +42.9% vs +110.8%/yr — rolling over.

07 · Operating margin

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

DMCC Speciality Chemicals Ltd's operating margin is 13.0% in the Jun 26 quarter, +0.0 percentage points against the same quarter a year ago. Across 10 fiscal years the operating margin has ranged 9.0% to 24.0%. The current quarter sits inside that band.

The latest quarter's operating margin is 13.0%, +0.0 pp against the same quarter a year ago. Across 10 fiscal years the operating margin has ranged 9.0%–24.0%.

Why the margin moved: operating margin went +0.2 pp year on year while gross margin went −11.4 pp — the gain came mostly from the gross line: input costs and pricing.

FY26: 11.0% Operating margin by fiscal year, %, line (left); year-on-year change in the margin, in percentage points, line (right). 10-year window.
within a 9.0–24.0% band over 10 years
operating marginYoY change (pp)
25%13%21%6.8%17%1.0%12%−4.8%7.8%−11%%%11%−2%FY17FY21FY26
25%13%21%6.8%17%1.0%12%−4.8%7.8%−11%%%11%−2%FY17FY21FY26
Jun 26: 13.0% operating margin (+0.0 pp YoY) Quarterly operating margin, %, line (left); year-on-year change in the margin, in percentage points, line (right). Last 12 quarters. Operating profit as a share of revenue, per quarter.
Operating marginYoY change (pp)
15%8.5%14%4.1%12%−0.3%10%−4.7%8.5%−9.1%%%13%0%Sep 23Dec 24Jun 26
15%8.5%14%4.1%12%−0.3%10%−4.7%8.5%−9.1%%%13%0%Sep 23Dec 24Jun 26
08 · Net profit

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

DMCC Speciality Chemicals Ltd earned ₹20.0 Cr of net profit in the Jun 26 quarter, +150.0% year on year. It is the 2nd consecutive quarter of growth. Full-year FY26 profit was ₹27.0 Cr. The 9-year compound rate is 5.3%. That is 7.9% of the quarter's revenue. The same quarter a year earlier earned ₹8.0 Cr.

Jun 26 profit was ₹20.0 Cr, +150.0% year on year — the 2nd consecutive quarter of growth. On the full year, FY26 printed ₹27.0 Cr (+22.7%), and the 9-year compound rate is 5.3%.

FY26 profit ₹27.0 Cr (+22.7% YoY) Net profit bars, ₹ Cr (left); YoY growth-% line (right). 10-year window. A bar is red when it is lower than the year before.
5.3% a year over 9 years
Net profitYoY growth
50311%37210%25108%126.8%0−95%₹ Cr%₹2722.7%FY17FY21FY26
50311%37210%25108%126.8%0−95%₹ Cr%₹2722.7%FY17FY21FY26
Jun 26: ₹20.0 Cr (+150.0% YoY) Quarterly net profit bars, ₹ Cr (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
2nd straight quarter of growth
Net profit (quarterly)YoY growth
22761%16539%11317%594%0−128%₹ Cr%₹20150%Sep 23Dec 24Jun 26
22761%16539%11317%594%0−128%₹ Cr%₹20150%Sep 23Dec 24Jun 26

Why profit moved: revenue contributed +99.2% and the margin +0.0 pp — the quarter was revenue-led, with the margin roughly flat.

Pace comparison, last four quarters: profit +39.6% vs revenue +48.0%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.

09 · Cash flow — the router

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 95% of DMCC Speciality Chemicals Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹−18.0 Cr of operating cash against ₹27.0 Cr of profit. After ₹7.0 Cr of capital spending, ₹−25.0 Cr was left as free cash.

FY26: operating cash of ₹−18.0 Cr against reported profit of ₹27.0 Cr, leaving free cash of ₹−25.0 Cr after ₹7.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 95% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

FY26: CFO ₹−18.0 Cr vs profit ₹27.0 Cr Operating cash flow and net profit by fiscal year, ₹ Cr; the line is free cash flow (CFO minus capital spending). 10-year window, annual resolution.
95% of 3-year profit arrived as cash
Operating cashNet profitFree cash
59302−27−56₹ Cr₹−18₹27₹−25FY17FY21FY26
59302−27−56₹ Cr₹−18₹27₹−25FY17FY21FY26
FY26: CFO = −67% of profit (three-year rate 95%) Operating cash as a share of net profit, per fiscal year, % (line). Dashed line = 100% — every unit of profit arriving as cash; outlier years shown pinned.
Conversion100%
329%223%117%10%−96%%−67%FY17FY21FY26
329%223%117%10%−96%%−67%FY17FY21FY26

Why conversion sits at 95%: the cash cycle held roughly steady between FY21 and FY26 — so conversion tracks profitability rather than the cycle.

Router verdict: no single sink dominates — the next section checks both the working-capital cycle and the capital spending.

10 · Where the cash goes

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

DMCC Speciality Chemicals Ltd's cash conversion cycle runs 83 days in FY26, down from 92 days in FY21. Capital spending ran ₹33.0 Cr over the last 3 years. At FY26 sales of ₹582 Cr each day of that cycle holds about ₹1.6 Cr, so roughly ₹132 Cr sits inside the business at any moment.

FY26: debtors at 60 days, inventory at 82 days — roughly 2.7 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 83 days, tighter than FY21's 92.

The full loop: cash goes out to suppliers and production on day 0; stock waits 82 days to sell; customers pay about 60 days after that; and suppliers themselves are paid at 60 days — netting out to the 83-day cycle.

In money terms: at FY26 sales of ₹582 Cr, each day of the cycle holds about ₹1.6 Cr — so the 83-day loop keeps roughly ₹132 Cr sitting inside the business at any moment.

FY26: a 83-day cash cycle Debtor days, inventory days, payable days and the cash conversion cycle by fiscal year. 10-year window.
−9 days vs FY21
Cash cycleInventory daysDebtor daysPayable days
1651146312−39days83d82d60d60dFY17FY19FY21FY23FY26
1651146312−39days83d82d60d60dFY17FY21FY26

On the investment side: capital spending of ₹33.0 Cr over the last 3 fiscal years against ₹49.0 Cr of depreciation — spending at or below maintenance level. Capital work-in-progress stands at ₹5.0 Cr (FY26) — capacity paid for but not yet earning.

FY26: capex ₹7.0 Cr, work-in-progress ₹5.0 Cr Capital spending per fiscal year, ₹ Cr (bars); capital work-in-progress, ₹ Cr (line). Quarterly capital-spending history is not held for India — annual is the honest resolution.
steady investment
CapexWork-in-progress
1078053270₹ Cr₹7₹5FY18FY20FY22FY24FY26
1078053270₹ Cr₹7₹5FY18FY22FY26

The synthesis: neither the cycle nor the build-out is hoarding the cash — the machine is reasonably clean.

11 · Return on capital

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.⚠ unverified

DMCC Speciality Chemicals Ltd earns a ROCE of 15% in FY26. That is up from a trough of 7% in FY23. Return on invested capital clears the cost of that capital by −0.9 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 4.6% net margin on 1.30× asset turns.

FY26 ROCE is 15%, recovered from a FY23 trough of 7% — the full ladder below shows the fall and the climb, undoctored.

🚨 Why the return is what it is — the wiring (FY26): 4.6% net margin × 1.30× asset turns × 1.80× balance-sheet leverage ≈ 10.8% on equity. Margin does its share; leverage is a meaningful part of the equation.

The capstone test — ROIC − WACC: 11.1% − 12.0% = a −0.9 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.

FY26: ROCE 15% Return on capital employed by fiscal year, % (line); ROIC by fiscal year, % (line). 9-year window, dips included. Dashed line = the 12.0% cost of capital used on this page.
the climb back from FY23's 7%
ROCEROIC (annual)WACC
46%35%24%13%1.7%%15%10.7%FY18FY22FY26
46%35%24%13%1.7%%15%10.7%FY18FY22FY26
Q4 FY26: ROCE 16.5% (TTM) vs WACC 12.0% Trailing-twelve-month ROCE and ROIC, per quarter, %; dashed line = the cost of capital. Last 12 quarters, put on a trailing-twelve-month basis and anchored to the annual figure.
ROCE (TTM)ROIC (TTM)WACC
19%15%11%6.6%2.5%%16.5%11.4%Q1 FY24Q2 FY25Q4 FY26
19%15%11%6.6%2.5%%16.5%11.4%Q1 FY24Q2 FY25Q4 FY26
12 · Debt

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.⚠ unverified

DMCC Speciality Chemicals Ltd carries total debt of ₹87.0 Cr against shareholder equity of ₹248 Cr as of Mar 26, a debt-to-equity of 0.35. On the annual view that ratio went from 0.48 in FY22 to 0.35 in FY26. Read the returns elsewhere on this page with that leverage in mind.

Mar 26: total debt of ₹87.0 Cr against shareholder equity of ₹248 Cr — a debt-to-equity of 0.35. On the annual view, debt-to-equity went from 0.48 (FY22) to 0.35 (FY26). Read the returns on this page with that leverage in mind.

FY26: debt ₹87.0 Cr at 0.35× equity Total debt by fiscal year, ₹ Cr (bars); debt-to-equity, × (line). 5-year window.
Total debtDebt-to-equity
1090.53×820.47×550.42×270.36×00.30×₹ Cr×₹870.35×FY22FY24FY26
1090.53×820.47×550.42×270.36×00.30×₹ Cr×₹870.35×FY22FY24FY26
Mar 26: debt ₹87.0 Cr, debt-to-equity 0.35 Total debt per quarter, ₹ Cr (bars); debt-to-equity, × (line). Last 12 quarters. India reports the full balance sheet half-yearly, so the intervening quarter carries the prior reading forward.
Total debt (quarterly)Debt-to-equity
950.44×710.37×480.30×240.22×00.15×₹ Cr×₹870.35×Jun 23Sep 24Mar 26
950.44×710.37×480.30×240.22×00.15×₹ Cr×₹870.35×Jun 23Sep 24Mar 26
13 · Ownership

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

No holder of DMCC Speciality Chemicals Ltd moved a full percentage point over the last two years — the register is quiet. Foreign institutions moved +0.1 points over the same window, to 0.1%. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — Domestic institutions: +0.3 points over 8 quarters to 1.5%; Foreign institutions: +0.1 points over 8 quarters to 0.1%; Promoters: +0.0 points over 8 quarters to 53.8%.

Fiscal-year ends: promoters +0.0 pts from Mar 24 to Mar 26 Shareholding at each fiscal-year end (March quarter), % of the company. 3 year-ends held.
PromotersForeign inst.Domestic inst.Public
58%43%27%11%−4.3%%53.8%0.1%1.3%44.8%Mar 24Mar 25Mar 26
58%43%27%11%−4.3%%53.8%0.1%1.3%44.8%Mar 24Mar 25Mar 26
A quiet register: no holder moved a full point in two years Shareholding by holder class, % of the company, quarterly, last 13 quarters.
PromotersForeign inst.Domestic inst.Public
58%43%27%11%−4.3%%53.8%0.1%1.5%44.5%Jun 23Dec 24Jun 26
58%43%27%11%−4.3%%53.8%0.1%1.5%44.5%Jun 23Dec 24Jun 26
14 · Safety line

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

DMCC Speciality Chemicals Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

15 · Related companies · Speciality Chemicals
CompanyScorePrice stageGrowth & earnings/35Capital efficiency/25Valuation/20Relative strength/20
1Panama Petrochem LtdPANAMAPET 74.9/100Favorable setup100% evidence LEADER 28.1/35 Revenue 45.9% · PAT 100% · OPM change 14 pp 100% evidence 14.9/25 ROCE 19.2% · OPM 22% 100% evidence 15.4/20 P/E 6.1× · PEG 0.55 100% evidence 16.5/20 RS sector 18.7% · RS bench 46.9% · 1Y 64.6%12 of 12 weeks ahead 100% evidence
Exact sum: 28.1 + 14.9 + 15.4 + 16.5 = 74.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
2Sunshield Chemicals Ltd530845 69.8/100Favorable setup76% evidence FADING 28.0/35 Revenue 12.9% · PAT 100% · OPM change 5 pp 95% evidence 16.6/25 ROCE 19.9% · OPM 16% 76% evidence 11.3/20 P/E 29.1× · PEG — 50% evidence 13.9/20 RS sector 2.3% · RS bench 24.5% · 1Y 16.2%10 of 11 weeks ahead 70% evidence
Exact sum: 28 + 16.6 + 11.3 + 13.9 = 69.8 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence.
3Vikram Thermo (India) Ltd530477 65.5/100Favorable setup67% evidence BREAKING OUT 25.5/35 Revenue 16.9% · PAT 41.9% · OPM change 8 pp 95% evidence 19.8/25 ROCE 36.2% · OPM 48% 76% evidence 7.9/20 P/E 24.3× · PEG — 50% evidence 12.3/20 RS sector — · RS bench 83.6% · 1Y —10 of 10 weeks ahead 25% evidence
Exact sum: 25.5 + 19.8 + 7.9 + 12.3 = 65.5 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence.
4Black Rose Industries LtdBLACKROSE 64.2/100Mixed-positive evidence72% evidence BREAKING OUT 22.0/35 Revenue 8.6% · PAT 28.6% · OPM change 6 pp 95% evidence 17.1/25 ROCE 18.7% · OPM 16% 95% evidence 14.5/20 P/E 19.2× · PEG — 50% evidence 10.6/20 RS sector — · RS bench 11.6% · 1Y —4 of 6 weeks ahead 25% evidence
Exact sum: 22 + 17.1 + 14.5 + 10.6 = 64.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
5Yasho Industries LtdYASHO 62.9/100Mixed-positive evidence87% evidence BREAKING OUT 29.3/35 Revenue 34.1% · PAT 100% · OPM change 7 pp 100% evidence 8.6/25 ROCE 8.9% · OPM 24% 100% evidence 12.0/20 P/E 87.6× · PEG 1.15 65% evidence 13.0/20 RS sector -2.4% · RS bench 102% · 1Y 131.1%11 of 11 weeks ahead 70% evidence
Exact sum: 29.3 + 8.6 + 12 + 13 = 62.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
6Privi Speciality Chemicals LtdPRIVISCL 59.9/100Mixed-positive evidence75% evidence FADING 25.0/35 Revenue 21.6% · PAT 62.1% · OPM change -1 pp 95% evidence 17.9/25 ROCE 22.3% · OPM 23% 76% evidence 9.5/20 P/E 39.7× · PEG — 15% evidence 7.5/20 RS sector -8.1% · RS bench 15.3% · 1Y 55.8%7 of 12 weeks ahead 100% evidence
Exact sum: 25 + 17.9 + 9.5 + 7.5 = 59.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
7Aether Industries LtdAETHER 58.4/100Mixed-positive evidence100% evidence BREAKING OUT 24.4/35 Revenue 34.4% · PAT 34.3% · OPM change -1 pp 100% evidence 10.7/25 ROCE 11.9% · OPM 31% 100% evidence 4.2/20 P/E 92.6× · PEG 8.9 100% evidence 19.1/20 RS sector 23.6% · RS bench 53.6% · 1Y 125.8%11 of 12 weeks ahead 100% evidence
Exact sum: 24.4 + 10.7 + 4.2 + 19.1 = 58.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
8DMCC Speciality Chemicals Ltdthis pageDMCC 56.8/100Mixed-positive evidence80% evidence TURNING 24.4/35 Revenue 49.7% · PAT 42.9% · OPM change 0 pp 95% evidence 11.0/25 ROCE 14.8% · OPM 13% 95% evidence 11.4/20 P/E 17.9× · PEG — 15% evidence 10.0/20 RS sector -12.3% · RS bench 10% · 1Y -6.5%6 of 12 weeks ahead 100% evidence
Exact sum: 24.4 + 11 + 11.4 + 10 = 56.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
9Pidilite Industries LtdPIDILITIND 56.7/100Mixed-positive evidence100% evidence FADING 22.6/35 Revenue 14.1% · PAT 21.5% · OPM change 1 pp 100% evidence 20.6/25 ROCE 31% · OPM 26% 100% evidence 7.9/20 P/E 60.2× · PEG 3.8 100% evidence 5.6/20 RS sector -15.4% · RS bench 6.4% · 1Y 1.3%11 of 12 weeks ahead 100% evidence
Exact sum: 22.6 + 20.6 + 7.9 + 5.6 = 56.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
10Tatva Chintan Pharma Chem LtdTATVA 56.0/100Mixed-positive evidence93% evidence BREAKING OUT 30.4/35 Revenue 41.1% · PAT 100% · OPM change 4 pp 100% evidence 6.5/25 ROCE 7.2% · OPM 19% 100% evidence 4.7/20 P/E 71.8× · PEG 5.63 65% evidence 14.4/20 RS sector -1.5% · RS bench 23.3% · 1Y 61.3%11 of 12 weeks ahead 100% evidence
Exact sum: 30.4 + 6.5 + 4.7 + 14.4 = 56 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
11Fineotex Chemical LtdFCL 54.0/100Mixed-positive evidence100% evidence LEADER 18.4/35 Revenue 91.5% · PAT 41% · OPM change -2 pp 100% evidence 12.7/25 ROCE 18.3% · OPM 16% 100% evidence 3.0/20 P/E 54.9× · PEG 4.19 100% evidence 19.9/20 RS sector 58% · RS bench 94.1% · 1Y 143.6%12 of 12 weeks ahead 100% evidence
Exact sum: 18.4 + 12.7 + 3 + 19.9 = 54 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
12Aarti Industries LtdAARTIIND 53.5/100Mixed-positive evidence100% evidence BREAKING OUT 27.7/35 Revenue 27% · PAT 100% · OPM change 3 pp 100% evidence 8.3/25 ROCE 6.9% · OPM 16% 100% evidence 9.0/20 P/E 34.2× · PEG 2.05 100% evidence 8.5/20 RS sector -8.2% · RS bench 15.1% · 1Y 30.8%8 of 12 weeks ahead 100% evidence
Exact sum: 27.7 + 8.3 + 9 + 8.5 = 53.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
13Kronox Lab Sciences LtdKRONOX 53.3/100Mixed-positive evidence65% evidence BREAKING OUT 9.4/35 Revenue 6.1% · PAT 11.6% · OPM change -1.1 pp 95% evidence 21.6/25 ROCE 36% · OPM 31.7% 95% evidence 10.8/20 P/E 22.8× · PEG — 15% evidence 11.5/20 RS sector — · RS bench 24.8% · 1Y —5 of 5 weeks ahead 25% evidence
Exact sum: 9.4 + 21.6 + 10.8 + 11.5 = 53.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
14Chemcon Speciality Chemicals LtdCHEMCON 51.1/100Mixed-positive evidence81% evidence TURNING 21.0/35 Revenue 16.7% · PAT 12% · OPM change 8 pp 95% evidence 10.7/25 ROCE 6.3% · OPM 23% 95% evidence 12.1/20 P/E 28.2× · PEG — 50% evidence 7.3/20 RS sector -21.7% · RS bench 13.7% · 1Y 4.3%6 of 10 weeks ahead 70% evidence
Exact sum: 21 + 10.7 + 12.1 + 7.3 = 51.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
15Vishnu Chemicals LtdVISHNU 47.7/100Mixed-negative evidence100% evidence BREAKING OUT 15.5/35 Revenue 16.5% · PAT 17.2% · OPM change -1 pp 100% evidence 11.3/25 ROCE 16.4% · OPM 15% 100% evidence 5.6/20 P/E 32.1× · PEG 2.82 100% evidence 15.3/20 RS sector 4.7% · RS bench 31.2% · 1Y 48.7%7 of 12 weeks ahead 100% evidence
Exact sum: 15.5 + 11.3 + 5.6 + 15.3 = 47.7 · Decision use: Price leads the evidence: RS versus the benchmark is 31.2%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
16Galaxy Surfactants LtdGALAXYSURF 47.3/100Mixed-negative evidence94% evidence BREAKING OUT 19.5/35 Revenue 27% · PAT 15.7% · OPM change 4 pp 100% evidence 9.4/25 ROCE 13.5% · OPM 14% 100% evidence 9.6/20 P/E 21.3× · PEG 4.39 100% evidence 8.8/20 RS sector -12.1% · RS bench 11.3% · 1Y -6.7%8 of 10 weeks ahead 70% evidence
Exact sum: 19.5 + 9.4 + 9.6 + 8.8 = 47.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
17Alkyl Amines Chemicals LtdALKYLAMINE 46.8/100Mixed-negative evidence100% evidence FADING 18.4/35 Revenue 5.1% · PAT 21% · OPM change 6 pp 100% evidence 15.6/25 ROCE 16.6% · OPM 25% 100% evidence 5.6/20 P/E 42.4× · PEG 5.37 100% evidence 7.2/20 RS sector -10.8% · RS bench 11.6% · 1Y -9.9%11 of 12 weeks ahead 100% evidence
Exact sum: 18.4 + 15.6 + 5.6 + 7.2 = 46.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
18Vinati Organics LtdVINATIORGA 44.4/100Mixed-negative evidence82% evidence TURNING 11.2/35 Revenue 5.1% · PAT 5.7% · OPM change -5 pp 95% evidence 17.5/25 ROCE 19.8% · OPM 24% 76% evidence 13.4/20 P/E 29.9× · PEG — 50% evidence 2.3/20 RS sector -28.7% · RS bench -9.8% · 1Y -23.9%0 of 12 weeks ahead 100% evidence
Exact sum: 11.2 + 17.5 + 13.4 + 2.3 = 44.4 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity.
19Amal LtdAMAL 43.0/100Mixed-negative evidence69% evidence 8.0/35 Revenue 79% · PAT -23.1% · OPM change -7 pp 95% evidence 16.4/25 ROCE 26% · OPM 18% 76% evidence 10.0/20 P/E 30.7× · PEG — 15% evidence 8.6/20 RS sector -18.2% · RS bench 15.4% · 1Y -20%0 of 12 weeks ahead 70% evidence
Exact sum: 8 + 16.4 + 10 + 8.6 = 43 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
20Platinum Industries LtdPLATIND 42.5/100Mixed-negative evidence74% evidence BASING 12.8/35 Revenue 9.6% · PAT 6.5% · OPM change -1 pp 95% evidence 12.3/25 ROCE 15.7% · OPM 12% 95% evidence 10.6/20 P/E 23.9× · PEG — 15% evidence 6.8/20 RS sector -10.6% · RS bench -6.1% · 1Y -22.8%0 of 10 weeks ahead 70% evidence
Exact sum: 12.8 + 12.3 + 10.6 + 6.8 = 42.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
21Grauer & Weil (India) LtdGRAUWEIL 41.5/100Mixed-negative evidence100% evidence TURNING 10.4/35 Revenue 10.1% · PAT 6.6% · OPM change -5 pp 100% evidence 16.1/25 ROCE 20.6% · OPM 16% 100% evidence 8.2/20 P/E 21.4× · PEG 4.01 100% evidence 6.8/20 RS sector -17.8% · RS bench 3.4% · 1Y -18.5%6 of 12 weeks ahead 100% evidence
Exact sum: 10.4 + 16.1 + 8.2 + 6.8 = 41.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
22Anupam Rasayan India LtdANURAS 41.5/100Mixed-negative evidence82% evidence ASLEEP 20.0/35 Revenue 51.7% · PAT 14.8% · OPM change -1 pp 95% evidence 10.5/25 ROCE 7.4% · OPM 25% 76% evidence 8.3/20 P/E 79.5× · PEG — 50% evidence 2.7/20 RS sector -21.7% · RS bench -1% · 1Y 9.8%0 of 12 weeks ahead 100% evidence
Exact sum: 20 + 10.5 + 8.3 + 2.7 = 41.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
23Neogen Chemicals LtdNEOGEN 40.5/100Mixed-negative evidence90% evidence LEADER 14.7/35 Revenue 18.1% · PAT 6.1% · OPM change 2 pp 100% evidence 6.7/25 ROCE 6.5% · OPM 19% 100% evidence 5.2/20 P/E 183× · PEG — 50% evidence 13.9/20 RS sector 22.9% · RS bench 52% · 1Y 59.6%12 of 12 weeks ahead 100% evidence
Exact sum: 14.7 + 6.7 + 5.2 + 13.9 = 40.5 · Decision use: Price leads the evidence: RS versus the benchmark is 52%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
24Paushak LtdPAUSHAKLTD 37.0/100Mixed-negative evidence81% evidence BREAKING OUT 11.9/35 Revenue 15.4% · PAT -15.7% · OPM change -1 pp 95% evidence 10.0/25 ROCE 8.3% · OPM 31% 95% evidence 7.5/20 P/E 42.4× · PEG — 50% evidence 7.6/20 RS sector -27.5% · RS bench 28% · 1Y -4.6%11 of 11 weeks ahead 70% evidence
Exact sum: 11.9 + 10 + 7.5 + 7.6 = 37 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
25Clean Science & Technology LtdCLEAN 36.3/100Mixed-negative evidence94% evidence BREAKING OUT 4.5/35 Revenue -0.4% · PAT -13.8% · OPM change -5 pp 100% evidence 18.5/25 ROCE 20.7% · OPM 36% 100% evidence 7.8/20 P/E 38.4× · PEG 6.24 100% evidence 5.5/20 RS sector -24.4% · RS bench 1.4% · 1Y -29.2%2 of 10 weeks ahead 70% evidence
Exact sum: 4.5 + 18.5 + 7.8 + 5.5 = 36.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
26Amines & Plasticizers LtdAMNPLST 35.5/100Mixed-negative evidence81% evidence ASLEEP 7.8/35 Revenue -12.4% · PAT -3% · OPM change 0.7 pp 95% evidence 14.0/25 ROCE 16.7% · OPM 9.9% 95% evidence 8.8/20 P/E 23.6× · PEG — 50% evidence 4.9/20 RS sector -19.4% · RS bench -9.2% · 1Y -27.6%5 of 10 weeks ahead 70% evidence
Exact sum: 7.8 + 14 + 8.8 + 4.9 = 35.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
27Transpek Industry LtdTRANSPEK 34.5/100Adverse evidence81% evidence TURNING 6.4/35 Revenue -5.2% · PAT -29.1% · OPM change -2.3 pp 95% evidence 9.1/25 ROCE 8.4% · OPM 13.3% 95% evidence 11.3/20 P/E 19.3× · PEG — 50% evidence 7.7/20 RS sector -19.7% · RS bench 11.7% · 1Y -4.7%4 of 10 weeks ahead 70% evidence
Exact sum: 6.4 + 9.1 + 11.3 + 7.7 = 34.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
28Thirumalai Chemicals LtdTIRUMALCHM 25.9/100Adverse evidence69% evidence BASING 13.1/35 Revenue -5.8% · PAT -36.9% · OPM change 12 pp 71% evidence 1.1/25 ROCE -3.1% · OPM 6% 95% evidence 10.0/20 P/E — · PEG — 0% evidence 1.7/20 RS sector -39.8% · RS bench -23.6% · 1Y -49%0 of 12 weeks ahead 100% evidence
Exact sum: 13.1 + 1.1 + 10 + 1.7 = 25.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.

16 · Frequently asked questions

Frequently asked questions

What is DMCC Speciality Chemicals Ltd's share price today?

DMCC Speciality Chemicals Ltd trades at ₹288, −4.9% over the past year. The company is valued at ₹717 Cr. The stock sits at 71% of its 52-week range of ₹207–₹321, +6.4% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 4 weeks in. — as of 11 September 2026.

What were DMCC Speciality Chemicals Ltd's latest quarterly results?

DMCC Speciality Chemicals Ltd reported revenue of ₹253 Cr and net profit of ₹20.0 Cr for the Jun 26 quarter. Revenue rose 99.2% and profit rose 150.0% year on year. Earnings per share were ₹8.18. The operating margin was 13.0%, 0.0 pp higher than a year earlier. — as of 11 September 2026.

What is DMCC Speciality Chemicals Ltd's revenue?

DMCC Speciality Chemicals Ltd reported revenue of ₹253 Cr in the Jun 26 quarter, +99.2% year on year. For the full FY26 fiscal year, revenue was ₹582 Cr (+35.0%). Over the last 9 years revenue compounded at 14.3% a year. — as of 11 September 2026.

What is DMCC Speciality Chemicals Ltd's profit?

DMCC Speciality Chemicals Ltd earned ₹20.0 Cr of net profit in the Jun 26 quarter, +150.0% year on year — the 2nd straight quarter of growth. Full-year FY26 profit was ₹27.0 Cr. The operating margin ran 13.0% in the latest quarter. — as of 11 September 2026.

What is DMCC Speciality Chemicals Ltd's market cap?

DMCC Speciality Chemicals Ltd's market capitalisation is ₹717 Cr at a share price of ₹288. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 11 September 2026.

What is DMCC Speciality Chemicals Ltd's P/E ratio?

DMCC Speciality Chemicals Ltd trades at a P/E of 17.9×, at the 24th percentile of its own 9-year range, against a long-run median of 28.6×. This is a comparison with the stock's own history, not a value call — as of 11 September 2026.

Does DMCC Speciality Chemicals Ltd pay a dividend?

Yes — DMCC Speciality Chemicals Ltd's dividend payout was 23% of profit in FY26, and it recorded a payout in 7 of its last 10 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 11 September 2026.

Is DMCC Speciality Chemicals Ltd overvalued?

On its own history, DMCC Speciality Chemicals Ltd looks cheap: its P/E of 17.9× has been cheaper only 24% of the time in 9 years (long-run median 28.6×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 11 September 2026.

Is DMCC Speciality Chemicals Ltd growing?

Yes — DMCC Speciality Chemicals Ltd is growing: latest-quarter revenue +99.2% year on year, profit +150.0%, and the margin +0.0 pp at 13.0%. The 9-year compound rates are 14.3% (revenue) and 5.3% (profit). The earnings engine currently reads: improving — as of 11 September 2026.

How is DMCC Speciality Chemicals Ltd performing?

DMCC Speciality Chemicals Ltd is in a confirmed uptrend, 4 weeks in. Its latest quarter's revenue rose 99.2% and profit rose 150.0% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 8 weeks. This describes what the data did, not a rating. — as of 11 September 2026.

What stage is DMCC Speciality Chemicals Ltd in?

Mixed — growth is normalizing off a hyper-growth base: profit growth has eased from +115.4% at its peak to +42.9% but is still expanding, ROCE lifting at 15.0%. The read comes from the last 12 quarters of growth (revenue growth +49.7% latest, profit growth +42.9% latest, eps growth +43.3% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 11 September 2026.

Is DMCC Speciality Chemicals Ltd in an uptrend?

Yes — the price is in a confirmed uptrend (week 4 of stage 2), trading +6.4% versus its 200-day average and at 71% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 11 September 2026.

Is DMCC Speciality Chemicals Ltd beating the market?

On recent form, yes — DMCC Speciality Chemicals Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 8 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.5 years the stock moved +396% against the NIFTY 500's +267% — ahead of the index over the full window. — as of 11 September 2026.

Will DMCC Speciality Chemicals Ltd's share price go up?

This page publishes no price forecast for DMCC Speciality Chemicals Ltd. What it measures instead: the share price is ₹288, the price is in a confirmed uptrend 4 weeks in. Its P/E of 17.9× sits at the 24th percentile of its own 9-year range. — as of 11 September 2026.

Who owns DMCC Speciality Chemicals Ltd?

Promoters hold 53.8% of DMCC Speciality Chemicals Ltd, foreign institutions 0.1%, domestic institutions 1.5% and the public 44.5% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 11 September 2026.

Does DMCC Speciality Chemicals Ltd have too much debt?

It is moderate — DMCC Speciality Chemicals Ltd's debt-to-equity is 0.44, and operating profit covers the interest bill 6×. FY26 borrowings were ₹110 Cr against equity of ₹248 Cr. Read the returns on this page with that leverage in mind — as of 11 September 2026.

What is DMCC Speciality Chemicals Ltd's capex?

DMCC Speciality Chemicals Ltd spent ₹33.0 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹7.0 Cr, with ₹5.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 11 September 2026.

What is DMCC Speciality Chemicals Ltd's cash flow?

DMCC Speciality Chemicals Ltd consumed ₹18.0 Cr of operating cash in FY26 — cash flowed out rather than in (free cash flow: ₹−25.0 Cr). Operating cash was negative while the company reported a profit of ₹27.0 Cr. Cash-flow resolution for India is annual. — as of 11 September 2026.

Is DMCC Speciality Chemicals Ltd's profit real cash?

Yes — over the last 3 fiscal years, 95% of DMCC Speciality Chemicals Ltd's reported profit arrived as operating cash. Though the latest year ran at -67% — the trend is the thing to watch. In FY26, operating cash was ₹−18.0 Cr against reported profit of ₹27.0 Cr. The cash then goes into a mix of the working-capital cycle and capacity. Cash-flow resolution is annual — as of 11 September 2026.

Where is DMCC Speciality Chemicals Ltd in its business cycle?

DMCC Speciality Chemicals Ltd's FY26 operating margin was 11.0%, against a 10-year band of 9.0%–24.0%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran 13.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 11 September 2026.

What growth does DMCC Speciality Chemicals Ltd's price assume?

At its price on 13 June 2026, DMCC Speciality Chemicals Ltd was priced for profit growth of about 13.5% a year. Profit itself has compounded 5.3% a year over the past 9 years. The figure reads the multiple backwards: the growth a buyer at that price was already paying for. — as of 11 September 2026.

What could break the DMCC Speciality Chemicals Ltd story?

The sharpest disagreement: annual EPS moved +27.0% against a −4.9% price move — the market has not yet caught up with the delivery. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 11 September 2026.

Is DMCC Speciality Chemicals Ltd a stock worth studying right now?

This is not investment advice. The machine read: DMCC Speciality Chemicals Ltd is coiled. The quarters are improving, yet the P/E sits at the 24th percentile of its own 9-year range — the business is moving before the market. The sharpest open question: whether the price catches up with earnings that have already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 11 September 2026.

Sector Alpha — machine-written from the numbers · Data as of 2026-09-11. Every chart on this page is drawn by deterministic code from the raw series — no forecasts, no price opinions, and nothing here is investment advice.

Not SEBI Registered !! Not Investment advice !!

Chat with this pageChat with pageChatChatGPTClaudePerplexityGoogle AI